Appendix
← Clinical Reader
Cardiology

Cardiac Syndrome X

Cardiac syndrome X (CSX) is characterized by typical or atypical anginal chest pain with no evidence of significant coronary vascular abnormalities visualized on angiogram. It is viewed as a type of ischemic heart disease with occurrence most prevalent in perimenopausal and postmenopausal females. To avoid the high morbidity and complications associated with this condition requires prompt diagnosis and treatment. This activity reviews the evaluation and treatment of CSX and highlights the role o

v1 · Reviewed Nov 7, 2026 by Automated Clinical Reviewer (Strict Verbatim v1)
  • To avoid the high morbidity and complications associated with this condition requires prompt diagnosis and treatment.
  • contemporary literature has supported subjects with CSX to have unfavorable cardiovascular events and a decreased quality of life.
  • Severe dysfunction poses a significant risk for atheroma formation and acute coronary syndrome (ACS).
  • Patients with established CSX often tend to have unfavorable cardiovascular events, leading to recurring hospitalizations, decreased quality of life, and poor prognostic outcomes.
  • The diagnosis of CSX is mainly of exclusion.
  • A thorough history and physical should be conducted prior to non-invasive and invasive testing
  • Before invasive procedures, an exercise tolerance test (ETT) or dobutamine stress echocardiogram (DSE) should be conducted.
  • Patients are reported to exhibit ST-segment depression on exercise stress tests and may also demonstrate transient ST depression on Holter monitoring.
  • Coronary angiography can provide an accurate measure of obstruction to the coronary vessels.
  • An invasive diagnostic modality to assess the endothelial function of coronary flow reserve (CFR) is accomplished by cardiac catheterization and Doppler guide-wire.
  • Noninvasive modalities such as brachial artery reactivity and peripheral arterial tonometry may also be employed to evaluate endothelial function.
  • All other ailments associated with microvascular dysfunction of the coronary vessels such as heart disease attributed to hypertension, amyloid induced cardiac disease, Takotsubo heart disease, Anderson Fabry disease, coronary slow-flow phenomenon (CSFP), also known as cardiac syndrome Y, a no-reflow phenomenon during a percutaneous coronary intervention (PCI) should be ruled out prior to concluding a CSX diagnosis.
  • Non-cardiac origins of chest pain should also be ruled out.
  • Pharmacologic management of CSX can be initiated by conventional anti-ischemic agents such as beta-blockers, nitrates, and calcium channel blockers.
  • nitrates alongside beta-blockers are currently the mainstay of treatment.
  • Beta-blockers (propranolol, nebivolol, and carvedilol) have been reported with 75% effectiveness in patients suffering from CSX and have been shown to improve exercise tolerance and symptoms.
  • Patients with CSX and anginal chest pain should be initiated on therapy with sublingual nitrates.
  • Lifestyle changes or improvements are also recommended
beta-blockers
Not specified in source
Adult
Not specified in source
Renal
Not specified in source
Duration
Not specified in source
nitrates
sublingual
Adult
Not specified in source
Renal
Not specified in source
Duration
Not specified in source
calcium channel blockers
Not specified in source
Adult
Not specified in source
Renal
Not specified in source
Duration
Not specified in source
  • Additional agents like angiotensin-converting enzyme (ACE) inhibitors, statins, and antianginals such as ranolazine may also be used.
  • Pain management with agents like tricyclic antidepressants (TCA) and xanthine derivatives has been reported to show effectiveness.
  • Calcium channel blockers (nifedipine, verapamil, diltiazem) may be an alternative therapy to beta-blockers if a therapeutic response is not achieved.
  • Ranolazine, a recent antianginal indicated for chronic angina used in patients with refractory angina, has also been reported to be an effective alternative for therapy.
  • Statins enhance the endothelium's vasodilatory effects and may be effective in patients with CSX.
  • ACE inhibitors have also been reported to be beneficial.
  • Agents such as xanthine derivatives (adenosine receptor blockers), aminophylline, and neural electrical stimulation have been proposed in select patients.
  • Other agents proposed for therapy include antidepressants such as tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs).
  • Imipramine is also advised by the American College of Cardiology for CSX patients unresponsive to beta-blockers, calcium channel blockers, and nitrates.
  • other treatment modalities such as cognitive-behavioral therapy (CBT) and neurostimulation may be considered.
  • The healthcare team should also monitor for recurring anginal symptoms as it can deteriorate the quality of a patient's life and prompt repeated hospital admissions.
  • Patients should be thoroughly educated on CSX and its potential impact.
  • Emphasis on medication compliance and lifestyle modifications should be encouraged.
  • Patients should also be advised about the diagnostic and therapeutic challenges with CSX as the pathophysiology is not entirely understood.
  • Based on recent literature, patients should be educated on their disease courses' potential long-term complications and prognosis.
  • Patients should also be educated on managing all underlying comorbidities and metabolic diseases that may further result in adverse cardiovascular events.
  • The primary care clinician should continually contact the cardiologist for any changes to their patient's medication regime and monitor the progress of the patient's disease course.
  • The primary care clinician should also investigate any underlying comorbidities and cardiovascular risk factors that may worsen CSX disease course and prognosis.
  • review
    Cardiac Syndrome X. StatPearls [Internet] — Arun U. Mahtani, Inderbir S. Padda, Gurpreet S. Johal — StatPearls Publishing, 2023

Decision support only. Verify against local protocols and current labeling. Source: www.ncbi.nlm.nih.gov